WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318654
CAS#: 98769-84-7
Description: Reboxetine is an antidepressant compound that selectively inhibits norepinephrine uptake for norepinephrine and serotonin transporters.
Hodoodo Cat#: H318654
Name: Reboxetine Mesylate
CAS#: 98769-84-7
Chemical Formula: C20H27NO6S
Exact Mass: 0.00
Molecular Weight: 409.500
Elemental Analysis: C, 58.66; H, 6.65; N, 3.42; O, 23.44; S, 7.83
Synonym: Reboxetine Mesylate; Reboxetine mesilate; Reboxetine (mesylate); Edronax; PNU 155950E;Reboxetine mesylate; Vestra (TN); AC1L2RIX; AC1Q6WCV; DSSTox_CID_25690; DSSTox_RID_81062; DSSTox_GSID_45690;
IUPAC/Chemical Name: (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid
InChi Key: XNHPNCDIRBAKCQ-WOJBJXKFSA-N
InChi Code: InChI=1S/C20H25NO6S/c1-2-25-17-10-6-7-11-18(17)27-20(16-8-4-3-5-9-16)19-14-21(12-13-26-19)15-28(22,23)24/h3-11,19-20H,2,12-15H2,1H3,(H,22,23,24)/t19-,20-/m1/s1
SMILES Code: CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3.CS(=O)(=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 409.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Mergui J, Jaworowski S. Risperidone-Induced Nocturnal Enuresis Successfully
Treated With Reboxetine. Clin Neuropharmacol. 2016 Mar 17. [Epub ahead of print]
PubMed PMID: 26992158.
2: Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K.
Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor
necrosis factor-α, interleukin-10, and depression-like behavior in mice after
lipopolysaccharide administration. Pharmacol Biochem Behav. 2016 May;144:7-12.
doi: 10.1016/j.pbb.2016.02.005. Epub 2016 Feb 15. PubMed PMID: 26892759.
3: Witten L, Bastlund JF, Glenthøj BY, Bundgaard C, Steiniger-Brach B, Mørk A,
Oranje B. Comparing Pharmacological Modulation of Sensory Gating in Healthy
Humans and Rats: The Effects of Reboxetine and Haloperidol.
Neuropsychopharmacology. 2016 Jan;41(2):638-45. doi: 10.1038/npp.2015.194. Epub
2015 Jul 1. PubMed PMID: 26129678.
4: Bozkurt H, Şahin S. Weight Loss Associated with Reboxetine Use in Adolescents.
J Child Adolesc Psychopharmacol. 2016 Feb;26(1):82-3. doi: 10.1089/cap.2015.0199.
Epub 2016 Jan 27. PubMed PMID: 26881861.
5: Roni MA, Rahman S. Effects of lobeline and reboxetine, fluoxetine, or
bupropion combination on depression-like behaviors in mice. Pharmacol Biochem
Behav. 2015 Dec;139(Pt A):1-6. doi: 10.1016/j.pbb.2015.10.006. Epub 2015 Oct 9.
PubMed PMID: 26455278.
6: Popławska M, Wróblewska D, Borowicz KK. Interactions between an antidepressant
reboxetine and four classic antiepileptic drugs in the mouse model of myoclonic
seizures. Pharmacol Rep. 2015 Dec;67(6):1141-6. doi:
10.1016/j.pharep.2015.04.016. Epub 2015 May 9. PubMed PMID: 26481533.
7: Braithwaite R. Reboxetine has no antidepressant effect at all. BMJ. 2015 Nov
3;351:h5842. doi: 10.1136/bmj.h5842. PubMed PMID: 26531816.
8: Caudill MM, Hunter AM, Cook IA, Leuchter AF. The Antidepressant Treatment
Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive
Disorder. Clin EEG Neurosci. 2015 Oct;46(4):277-84. doi:
10.1177/1550059414532443. Epub 2014 Sep 24. PubMed PMID: 25258429.
9: Kruchinina AD, Gengin MT. [Effect of reboxetine on activity of
carboxypeptidase E in the nerve tissue of rats]. Biomed Khim. 2015
Sep-Oct;61(5):657-60. doi: 10.18097/PBMC20156105657. Russian. PubMed PMID:
26539877.
10: Metzger CD, Wiegers M, Walter M, Abler B, Graf H. Local and Global Resting
State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by
Reboxetine and Amisulpride in Healthy Subjects. Int J Neuropsychopharmacol. 2015
Jul 25;19(2). pii: pyv080. doi: 10.1093/ijnp/pyv080. PubMed PMID: 26209860;
PubMed Central PMCID: PMC4772816.
11: Ghanizadeh A. A systematic review of reboxetine for treating patients with
attention deficit hyperactivity disorder. Nord J Psychiatry. 2015
May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21. Review.
PubMed PMID: 25415763.
12: Penmatsa A, Wang KH, Gouaux E. X-ray structures of Drosophila dopamine
transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol. 2015
Jun;22(6):506-8. doi: 10.1038/nsmb.3029. Epub 2015 May 11. PubMed PMID: 25961798;
PubMed Central PMCID: PMC4608549.
13: Yucel A, Yucel N, Ozcan H, Gulec M, Aydin A. Fluoxetine associated with
thrombocytopenia and treatment with reboxetine: 3 cases. J Clin Psychopharmacol.
2015 Jun;35(3):354-5. doi: 10.1097/JCP.0000000000000301. PubMed PMID: 25822478.
14: Gray VC, Hughes RN. Drug-, dose- and sex-dependent effects of chronic
fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory
in rats. Behav Brain Res. 2015 Mar 15;281:43-54. doi: 10.1016/j.bbr.2014.12.023.
Epub 2014 Dec 16. PubMed PMID: 25523028.
15: Hughes S, Hickey L, Donaldson LF, Lumb BM, Pickering AE. Intrathecal
reboxetine suppresses evoked and ongoing neuropathic pain behaviours by restoring
spinal noradrenergic inhibitory tone. Pain. 2015 Feb;156(2):328-34. doi:
10.1097/01.j.pain.0000460313.73358.31. PubMed PMID: 25599454.
16: Bhagya V, Srikumar BN, Raju TR, Shankaranarayana Rao BS. The selective
noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits,
biochemical changes, and hippocampal synaptic plasticity in an animal model of
depression. J Neurosci Res. 2015 Jan;93(1):104-20. doi: 10.1002/jnr.23473. Epub
2014 Aug 21. PubMed PMID: 25146499.
17: Wiles NJ, Fischer K, Cowen P, Nutt D, Peters TJ, Lewis G, White IR. Allowing
for non-adherence to treatment in a randomized controlled trial of two
antidepressants (citalopram versus reboxetine): an example from the GENPOD trial.
Psychol Med. 2014 Oct;44(13):2855-66. doi: 10.1017/S0033291714000221. Epub 2014
Mar 3. PubMed PMID: 25065692; PubMed Central PMCID: PMC4131263.
18: Graf H, Wiegers M, Metzger CD, Walter M, Grön G, Abler B. Erotic stimulus
processing under amisulpride and reboxetine: a placebo-controlled fMRI study in
healthy subjects. Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu004.
doi: 10.1093/ijnp/pyu004. PubMed PMID: 25612894; PubMed Central PMCID:
PMC4368880.
19: Bruno A, Zoccali R, Bellinghieri PM, Pandolfo G, De Fazio P, Spina E,
Muscatello MR. Reboxetine adjuvant therapy in patients with schizophrenia showing
a suboptimal response to clozapine: a 12-week, open-label, pilot study. J Clin
Psychopharmacol. 2014 Oct;34(5):620-3. doi: 10.1097/JCP.0000000000000196. PubMed
PMID: 25118083.
20: Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez
R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe
AE, Fernandez de Corres B, Ibáñez A, Huerta R; Abordaje Síntomas Negativos
Esquizofrenia Group. Double-blind, placebo-controlled study of the efficacy of
reboxetine and citalopram as adjuncts to atypical antipsychotics for negative
symptoms of schizophrenia. J Clin Psychiatry. 2014 Jun;75(6):608-15. doi:
10.4088/JCP.13m08551. PubMed PMID: 25004184.
